MichaelCecchiniMD

PubMed

• Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
  Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada L...> ;NPJ Precision Oncology. 2024 Apr 8
• NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
  Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward Kim, Stacey Stein, ...> ;British Journal of Cancer. 2024 Feb 1
• 2 citations
  Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US.
  Madhav Kc, Jane Fan, Terry Hyslop, Sirad Hassan, Michael Cecchini, Shi-Yi Wang, Andrea Silber, Michael S Leapman, Ira Leeds, Stephanie B Wheeler, Lisa P Spees, Cary P ...> ;JAMA Network Open. 2023 Jul 3
• Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer.
  Gabrielle W Peters, Wesley Talcott, Nicholas V Peters, Andrew Dhanasopan, Jill Lacy, Michael Cecchini, Jeremy Kortmansky, Stacey Stein, Stephen Lattanzi, Daniel Boffa,...> ;Journal of Gastrointestinal Oncology. 2023 Jun 30
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
  Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kort...> ;Cancer Research Communications. 2023 Jun 1
• 5 citations
  Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.
  Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, Glenn Begley, Michael Cecchini, Joseph Paul Eder, Francois Ghiringhelli, Antoine Italiano, Marina Kochetko...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
  Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph P Eder, Kurt A Schalper, Alice P Chen, Patricia LoRusso> ;Cancer Research Communications. 2023 Jun 1
• 1 citations
  Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer.
  Meriem Mokhtech, Joseph A Miccio, Kimberly Johung, Michael Cecchini, Stacey Stein, Amol K Narang, Joseph M Herman, John Kunstman, Michael G Haddock, Christopher J Anke...> ;American Journal of Clinical Oncology. 2022 Nov 1
• 1 citations
  Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential.
  Mar Giner-Calabuig, Seila De Leon, Julian Wang, Tara D Fehlmann, Chinedu Ukaegbu, Joanna Gibson, Miren Alustiza-Fernandez, Maria-Dolores Pico, Cristina Alenda, Maite H...> ;British Journal of Cancer. 2022 Jun 1
• Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observati...
  Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, ...> ;JMIR Cancer. 2022 May 19
• 2 citations
  Impact of early detection on cancer curability: A modified Delphi panel study.
  Lee Schwartzberg, Michael S Broder, Sikander Ailawadhi, Himisha Beltran, L Johnetta Blakely, G Thomas Budd, Laurie Carr, Michael Cecchini, Patrick Cobb, Anuraag Kansal...> ;Plos One. 2022 Jan 1
• 5 citations
  Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.
  Chen Li, Ana Ferro, Shivani K Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Michael Cecchini, Katrina S Pedersen, Tae You Kim, Irmarie...> ;Communications Medicine. 2022 Jan 1
• 1 citations
  Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequ...
  Yang Guo, Ferenc Czeyda-Pommersheim, Joseph A. Miccio, Sowmya Mahalingam, Michael Cecchini, Jay Pahade> ;Abdominal Radiology. 2021 Sep 23
• 2 citations
  Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.
  Gabrielle W. Peters, Weiwei Tao, Wei Wei, Joseph A. Miccio, Krishan R. Jethwa, Michael Cecchini, Kimberly L. Johung> ;The Oncologist. 2021 Aug 1
• Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.
  Joanna Gibson, Karin E. Finberg, ILKe Nalbantoglu, Michael Cecchini, Zenta Walther, Jeffrey Sklar, Joseph Paul Eder, Sarah B. Goldberg> ;The Lancet. Oncology. 2021 Mar 1
• 5 citations
  Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national c...
  Joseph A. Miccio, Wesley J. Talcott, Timil Patel, Henry S. Park, Michael Cecchini, Ronald R. Salem, Sajid A. Khan, Stacey Stein, Jeremy S. Kortmansky, Jill Lacy, Amol ...> ;Clinical and Translational Radiation Oncology. 2021 Mar 1
• 16 citations
  Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database
  Johannes Uhlig, Michael Cecchini, Amar H. Sheth, Stacey Stein, Jill Lacy, Hyun Soo Kim> ;Journal of the National Comprehensive Cancer Network. 2021 Feb 2
• Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System
  Timil Patel, Joseph A. Miccio, Michael Cecchini, Thejal Srikumar, Stacey Stein, Jeremy Kortmanksy, Kimberly L. Johung, Jill Lacy> ;Journal of Gastrointestinal Oncology. 2021 Jan 1
• 5 citations
  A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
  Michael Cecchini, Jeremy S. Kortmansky, Can Cui, Wei Wei, Jaykumar R. Thumar, Nataliya Volodymyrivna Uboha, Navid Hafez, Jill Lacy, Neal A. Fischbach, Kert D. Sabbath,...> ;Cancer. 2020 Dec 22
• 2 citations
  A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline ...
  Michael Cecchini, Joseph A. Miccio, Jay Pahade, Jill Lacy, Ronald R. Salem, Skyler B. Johnson, Adriana Blakaj, Stacey Stein, Jeremy S. Kortmansky, Kimberly L. Johung> ;Pancreas. 2020 Aug 1
• 122 citations
  Targeted Therapies in Advanced Gastric Cancer.
  Timil Patel, Michael Cecchini> ;Current Treatment Options in Oncology. 2020 Jul 28
• 27 citations
  Challenges with Novel Clinical Trial Designs: Master Protocols
  Michael Cecchini, Eric H. Rubin, Gideon M. Blumenthal, Kassa Ayalew, Howard A. Burris, Michele Russell-Einhorn, Hildy Dillon, H. Kim Lyerly, Gregory H. Reaman, Scott A...> ;Clinical Cancer Research. 2019 Apr 1
• 4 citations
  Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.
  Michael Cecchini, Zenta Walther, Jeffrey Sklar, Ranjit S. Bindra, Daniel P. Petrylak, Joseph Paul Eder, Sarah B. Goldberg> ;The Lancet. Oncology. 2018 Jan 1
• 3 citations
  Introduction to the Yale Precision Medicine Tumor Board.
  Michael Cecchini, Zenta Walther, Jeffrey Sklar, Ranjit S. Bindra, Daniel P. Petrylak, Joseph Paul Eder, Sarah B. Goldberg> ;The Lancet. Oncology. 2018 Jan 1
• 1 citations
  EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
  Michael Cecchini, Jeffrey Sklar, Jill Lacy> ;Journal of the National Comprehensive Cancer Network. 2017 Sep 1
• Join now to see all

Lectures

• NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018